MDACC Study No:2004-0874 ( NCT No: NCT00242502)
Title:A Phase II Study of the Combination of Avastin and Erlotinib in Patients with Unresectable Hepatocellular Carcinoma
Principal Investigator:Ahmed Kaseb
Treatment Agent:Avastin; Erlotinib
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if treatment with Avastin
combined with Tarceva (OSI-774/erlotinib hydrochloride) can help to slow the
growth of advanced liver cancer. The safety of this combination treatment
will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Gastrointestinal
Phase of Study:Phase II
Treatment Agents:Avastin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Hospitalization is not required for this study.
Supported By:N/A
Return Visit:Patients must come to MDACC every two weeks for Avastin infusion.
Home Care:Patient will take erlotinib orally on a daily basis at home.
Study tests and evaluations will be performed at MDACC.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Ahmed Kaseb
Dept:Gastrointestinal Medical Oncology
For Clinical Trial Enrollment:713-792-2828
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults